May, 2022

Global
News / Press Releases
Astellas to Present New Research Further Supporting Roxadustat Safety in the Treatment of Symptomatic Anemia of Chronic Kidney Disease at 59th ERA Congress 2022
Three abstracts provide additional insights into roxadustat safety profile and effect on iron parameters TOKYO, May 16, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced the presentation of new roxadustat data at the 59 th European Renal Association (ERA) Congress, taking place May 19–22, 2022. Two presentations focus on pooled analyses from...
Read More
Global
News / Press Releases
Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress
Abstracts represent exciting research progress across four cancers where patients have limited treatment options TOKYO, May 12, 2022 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new research during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Hybrid...
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
Read More
Global
News / General News
We renovated our recruitment site.
Read More

May, 2024

Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme and Performance-linked Stock Delivery Scheme for the Domestic and Global Astellas Group Executives
Read More
Global
News / Press Releases
Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme
Read More
Global
News / Press Releases
Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual Meeting
TOKYO, May 13, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) will share new research from across its innovative portfolio of approved and investigational cancer therapies during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 - June 4. A total of 16 abstracts will be presented, including new data from pivotal trials...
Read More
Global
News / Press Releases
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
- Leverages Poseida’s proprietary allogeneic CAR-T platform to develop innovative convertibleCAR ® programs targeting solid tumors - TOKYO and SAN DIEGO, May 1, 2024 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, President and CEO: Kristin Yarema, “Poseida”) today announced that Xyphos Biosciences, Inc., (a wholly...
Read More

Apr, 2024

Global
News / Press Releases
Change in Definition of Core Basis in Financial Results
TOKYO, April 25, 2024 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced that at the meeting of the Board of Directors held today, it decided to change the definition of core basis in consolidated financial statements from the fiscal year 2024 (FY2024) ending March 31, 2025 onward. Astellas has been applying International Financial Reporting Standards...
Read More

Apr, 2024

Global
News / IR
Posted Financial Results for FY2023
Read More
Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Feb, 2024

Global
News / IR
Posted Financial Results for Q3/FY2023
Read More

Dec, 2023

Global
News / General News
Astellas Updates “Contact for Potential Acquisition of Astellas’ R&D Programs” Section on its Corporate Website
Astellas Pharma Inc. (“Astellas”) updated the information about Astellas terminated R&D programs on “Contact for Potential Acquisition of Astellas’ R&D programs” section on its corporate website. https://www.astellas.com/en/contact-r-and-d-programs Astellas has been working on the effective utilization of its assets from programs for which it has terminated R&D by considering the continuation of R...
Read More

Nov, 2023

Global
News / IR
Posted Financial Results for Q2/FY2023
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match.

Back to Newsroom